Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F04%3A00002140" target="_blank" >RIV/61989592:15310/04:00002140 - isvavai.cz</a>
Alternative codes found
RIV/61389030:_____/04:00000293 RIV/61989592:15110/04:00000807 RIV/61989592:15110/04:00007062
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines
Original language description
Currently, mechanisms leading to both apoptosis induction and the development of hormone-independence of prostate carcinoma cells are intensively studied. Attention is also given to the possibility of restoring cell sensitivity to hormone-antagonists. The present study focuses on the effect of the combined synthetic cyclin-dependent kinase [CDK] inhibitor, olomoucine and the antiandrogen bicalutamide on hormone-insensitive (DU-145) and hormone-sensitive (LNCaP) prostate cancer cell lines. In both cell lines reduction in cell viability was significantly higher when olomoucine and bicalutamide were applied in combination when compared to separate application of both these drugs. The setting of optimal concentrations for both substances was important forthe final effect on both cell lines. The proliferation arrest was accompanied by a decrease in cyclin D1 expression and the activation of p21Waf1/Cip1 and p27Kip1 pathways in both cell lines. Contrary to the previously described effect of
Czech name
Synergický účinek olomoucinu, inhibitoru cyklin-dependentní kinasy (CDK), a bikalutamidu, antagonistu androgenu, na buněčnou linii rakoviny prostaty
Czech description
Byl studován synergický účinek olomoucinu, inhibitoru cyklin-dependentní kinasy (CDK), a bikalutamidu, antagonistu androgenu, na buněčnou linii rakoviny prostaty.
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
ED - Physiology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/GA301%2F02%2F0475" target="_blank" >GA301/02/0475: Purine inhibitors of cyclin-dependent kinases as anticancer and antimitotic compounds</a><br>
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2004
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
—
Volume of the periodical
51
Issue of the periodical within the volume
5
Country of publishing house
SK - SLOVAKIA
Number of pages
10
Pages from-to
358-367
UT code for WoS article
—
EID of the result in the Scopus database
—